Enveric Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2026-02-11.
Enveric Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 11, 2026. The filing reports $1.45M sold. Its industry group is Biotechnology. It names Joseph Tucker (Chief Executive Officer and Director), Kevin Coveney (Chief Financial Officer), Michael Webb (Director) (SEC Form D, February 11, 2026).
Sell to companies like Enveric Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Enveric Biosciences, Inc.
Free to see. No signup.
More on the people and the money behind Enveric Biosciences, Inc., from the filings we hold.
H.C. Wainwright & Co., LLC received sales compensation on this raise and on 11 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Massachusetts, filed in February 2026, largest first.
Get an email when Enveric Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Enveric Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Enveric Biosciences, Inc. →Get the full cited report on Enveric Biosciences, Inc.
What the filing shows about Enveric Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Enveric Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Enveric Biosciences, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Enveric Biosciences, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $1.45M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Joseph Tucker is named as Chief Executive Officer and Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
Kevin Coveney is named as Chief Financial Officer on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
Michael Webb is named as Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
George Kegler is named as Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
Marcus Schabacker is named as Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
Frank Pasqualone is named as Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
Sheila DeWitt is named as Director on the Form D that Enveric Biosciences, Inc. filed with the SEC on 11 February 2026, one of 7 people that filing names.
7 people named on the filing — 2 holding an executive role and 5 as directors only.
Named as of the 2026-02-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Enveric Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Enveric Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enveric Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Enveric Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Enveric Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Enveric Biosciences, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/enveric-biosciences-inc-form-d-26000002